COVID-19FinancialRegulatory

The U.S. Just Signed A $450 Million Coronavirus Vaccine Contract With Johnson & Johnson

March 30, 2020 / Thomas Brewster, Forbes Staff

The Trump administration is spending nearly half a billion dollars on one company in the race to find a coronavirus vaccine.

That’s according to a $456 million order with Johnson & Johnson’s Pharmaceuticals arm Janssen, which specified a “new vaccine asset for 2019 Novel Coronavirus (COVID-19),” Forbes found. It’s the largest reported amount spent on a vaccine project to date, even though the pharma giant hasn’t yet started any clinical trials as other firms have.

The deal was signed with the Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) on March 27, 2020. It followed another order, made as part of the same contract with Janssen, for $150 million on March 20, 2020, for a “new antiviral” for COVID-19.

A spokesperson from Johnson & Johnson didn’t provide any more details on the specific order, but confirmed the $456 million award related to a collaboration with ASPR’s Biomedical Advanced Research and Development Authority (BARDA), as announced in February. That work was built on previous contracts for developing countermeasures for other influenzas. The value of the coronavirus-specific work hadn’t previously been revealed and is the largest known contract for a coronavirus vaccine to date.

READ THE REST HERE

Print Friendly, PDF & Email
Tags

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button
Close